Eight months old. Half-owned by a venture capital firm. Just over $400 million in stock.
According to reporting by Eric Newcomer, who obtained a letter documenting the deal, Anthropic has acquired Coefficient Bio, a stealth startup focused on AI models for biological research, in an all-stock transaction. Anthropic and Dimension both declined to comment. There is no official Anthropic announcement. The verified source for this item is Newcomer’s independent reporting; readers should note this is single-source coverage pending any official confirmation.
Coefficient Bio was backed by Dimension VC, which reportedly owned approximately 50% of the company at the time of acquisition. Dimension is claiming a 38,513% IRR on its investment, according to Newcomer’s reporting, a figure that reflects both the extraordinarily short holding period (roughly eight months) and the premium Anthropic paid for a company with no extended track record. Whatever Dimension paid to establish its 50% position, the return multiple is a direct function of how much Anthropic valued the team and the research direction over provable commercial traction.
Coefficient Bio was working on AI models for biological research. Co-founder Samuel Stanton wrote in January: “We’re ushering biopharma into the Intelligence Age. It will change everything about how the industry learns and makes decisions.” Newcomer describes the company’s ambition as “nothing short of artificial superintelligence for science.” Those are large claims from an eight-month-old company. Anthropic’s willingness to pay just over $400 million in stock suggests it found the research direction credible enough to acquire rather than build.
The acquired team joins Anthropic’s Health Care Life Sciences division, led by Eric Kauderer-Abrams. Coefficient Bio is the third known acquisition in Anthropic’s recent history, Newcomer’s reporting notes that Bun and Vercept preceded it.
The strategic read here is deliberate vertical expansion. Anthropic isn’t buying Coefficient Bio to add general AI capability. It already has that. It’s buying domain-specific biological research expertise and positioning it inside a dedicated healthcare and life sciences structure. That’s a different move, one that signals Anthropic sees healthcare and biopharma not as an application category to serve via API, but as a domain to develop native intelligence for.
For enterprise buyers in life sciences and pharmaceutical R&D, this matters. Anthropic now has an internal team whose explicit mandate is AI for biological research. That team will inform Claude’s development roadmap in ways that third-party developers building on Claude cannot anticipate. If your organization is evaluating AI platforms for scientific research or drug development workflows, Anthropic’s healthcare-specific positioning has just changed.
Context worth noting: reports have emerged, separately, of Anthropic considering an October IPO at a potential $2 trillion valuation. If accurate, the Coefficient Bio acquisition fits a pre-IPO narrative, expanding into high-value verticals to demonstrate total addressable market breadth before a public offering. Neither the IPO timing nor the valuation figure is confirmed; they come from a single aggregation source and should be held loosely. A Wire follow-up item has been flagged.
Watch for an official Anthropic statement, which would upgrade this item from single-source to confirmed. Watch also for Coefficient Bio’s research to surface in Anthropic product announcements, that’s the earliest indicator of whether the acquisition is integrating as expected.